About this trial
This quasi-experimental study aims to evaluate the effect of combined autogenic relaxation and Surah Ar-Rahman murottal therapy on anxiety, sleep quality, and hemodynamic parameters in hemodialysis patients. A pretest-posttest control group design will be used involving 76 participants undergoing routine hemodialysis. Participants will be assigned to an intervention group receiving structured autogenic relaxation followed by murottal therapy and a control group receiving standard care with music listening. Anxiety, sleep quality, and hemodynamic parameters will be measured at baseline and after a 6-week intervention period. The findings are expected to support the use of non-pharmacological and spiritual-based interventions in improving psychological and physiological outcomes in hemodialysis patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients diagnosed with stage V chronic kidney disease.
Undergoing scheduled hemodialysis at least twice a week for 6 weeks.
Outpatients and aged 18-65 years.
Muslim.
Disqualifiers
Having a severe heart condition or an unstable critical condition.
Having a severe psychiatric disorder (schizophrenia, major depression).
Having a cognitive, hearing, or speech disorder that impedes communication.
Taking antidepressants, anxiolytics, or neuroleptics that may affect psychological measurement results.
Trial design
Parallel
Treatments tested in this trial
Autogenic Relaxation and Surah Ar-Rahman Murottal Therapy
BehavioralA structured non-pharmacological intervention consisting of autogenic relaxation techniques including breathing regulation, muscle relaxation, and self-suggestion, followed by listening to Surah Ar-Rahman murottal recitation using earphones. Each session lasts 10-15 minutes and is conducted twice weekly for six weeks during routine hemodialysis.
listening to dangdut music
Other interventionlistening to dangdut music for 10 to 15 minutes within 6 weeks
Treatment groups
Trial outcomes
Primary outcomes
Anxiety
Change in anxiety level measured using the Zung Self-Rating Anxiety Scale (ZSAS; range 20-80), where higher scores indicate greater anxiety, from baseline to after completion of the 6-week intervention.
Sleep Quality
Change in sleep quality measured using the Pittsburgh Sleep Quality Index (PSQI; range 0-21), where higher scores indicate poorer sleep quality, from baseline to after completion of the 6-week intervention.
Blood Presure
Change in systolic blood pressure (mmHg), measured using a calibrated digital sphygmomanometer, from baseline to after completion of the 6-week intervention.
Heart Rate
Change in heart rate (beats per minute, bpm), measured using a digital bedside patient monitor, from baseline to after completion of the 6-week intervention.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: